"Sou\u010Dasn\u00E9 pohledy na l\u00E9\u010Dbu nemocn\u00FDch v pokro\u010Dil\u00E9m stadiu Hodgkinova lymfomu"@cs . "Sou\u010Dasn\u00E9 pohledy na l\u00E9\u010Dbu nemocn\u00FDch v pokro\u010Dil\u00E9m stadiu Hodgkinova lymfomu" . . "Onkologie" . . "Pomoc\u00ED modern\u00EDch l\u00E9\u010Debn\u00FDch strategi\u00ED m\u00E1 \u0161anci na vyl\u00E9\u010Den\u00ED v\u00EDce ne\u017E 80 % pacient\u016F s Hodgkinov\u00FDm lymfomem (HL) ve v\u011Bku do 60 let. C\u00EDlem sou\u010Dasn\u00FDch l\u00E9\u010Debn\u00FDch postup\u016F je zachov\u00E1n\u00ED vysok\u00E9ho po\u010Dtu vyl\u00E9\u010Den\u00FDch pacient\u016F a omezen\u00ED toxicity. U pacient\u016F v pokro\u010Dil\u00E9m stadiu HL je celkov\u00E9 p\u0159e\u017Eit\u00ED o 10 % vy\u0161\u0161\u00ED po l\u00E9\u010Db\u011B eskalovan\u00FDm BEACOPP oproti ABVD, proto je 6 cykl\u016F eskalovan\u00E9ho BEACOPP standardem l\u00E9\u010Dby u pacient\u016F do 60 let. U pacient\u016F nad 60 let z\u016Fst\u00E1v\u00E1 standardem l\u00E9\u010Dby 6 cykl\u016F ABVD. Po chemoterapii je mo\u017En\u00E9 vynechat radioterapii u pacient\u016F s negativn\u00EDm n\u00E1lezem podle pozitronov\u00E9 emisn\u00ED tomografie (PET). \u010Cek\u00E1 se na dlouhodob\u00E9 v\u00FDsledky studi\u00ED se stratifikac\u00ED l\u00E9\u010Dby podle interim PET a studi\u00ED s brentuximab vedotinem v kombinaci s chemoterapi\u00ED v prvn\u00ED linii." . "11120" . "Sou\u010Dasn\u00E9 pohledy na l\u00E9\u010Dbu nemocn\u00FDch v pokro\u010Dil\u00E9m stadiu Hodgkinova lymfomu" . "RIV/00216208:11120/14:43908667" . . "brentuximab vedotin; FDG-PET; BEACOPP; ABVD; Hodgkin lymphoma"@en . . "More than 80 % of patients with Hodgkin lymphoma (HL) younger than 60 years are likely to be cured with modern treatment strategies. The goal of current treatment approaches is to maintain the high treatment efficacy and to reduce the toxicity. BEACOPP escalated has a 10 % overall survival advantage over ABVD in patients with advanced-stage HL, therefore 6 cycles of BEACOPP escalated has become the standard of care for patients younger than 60 years. Six cycles of ABVD remain the standard of care for patients over 60 years. Radiotherapy could be omitted in patients with a negative positrone emission tomography (PET) finding after chemotherapy. Mature trial results of the treatment stratification based on PET and trial results of brentuximab vedotin combined with chemotherapy in the first-line treatment are awaited."@en . "Current treatment approaches in patients with advanced-stage Hodgkin lymphoma"@en . "1"^^ . . "M\u00F3cikov\u00E1, Heidi" . "CZ - \u010Cesk\u00E1 republika" . . "RIV/00216208:11120/14:43908667!RIV15-MSM-11120___" . "1802-4475" . "Current treatment approaches in patients with advanced-stage Hodgkin lymphoma"@en . "1"^^ . . . . "46091" . . . . "8" . "[02C44E810383]" . . "4"^^ . "I" . "Sou\u010Dasn\u00E9 pohledy na l\u00E9\u010Dbu nemocn\u00FDch v pokro\u010Dil\u00E9m stadiu Hodgkinova lymfomu"@cs . . "3" . . "Pomoc\u00ED modern\u00EDch l\u00E9\u010Debn\u00FDch strategi\u00ED m\u00E1 \u0161anci na vyl\u00E9\u010Den\u00ED v\u00EDce ne\u017E 80 % pacient\u016F s Hodgkinov\u00FDm lymfomem (HL) ve v\u011Bku do 60 let. C\u00EDlem sou\u010Dasn\u00FDch l\u00E9\u010Debn\u00FDch postup\u016F je zachov\u00E1n\u00ED vysok\u00E9ho po\u010Dtu vyl\u00E9\u010Den\u00FDch pacient\u016F a omezen\u00ED toxicity. U pacient\u016F v pokro\u010Dil\u00E9m stadiu HL je celkov\u00E9 p\u0159e\u017Eit\u00ED o 10 % vy\u0161\u0161\u00ED po l\u00E9\u010Db\u011B eskalovan\u00FDm BEACOPP oproti ABVD, proto je 6 cykl\u016F eskalovan\u00E9ho BEACOPP standardem l\u00E9\u010Dby u pacient\u016F do 60 let. U pacient\u016F nad 60 let z\u016Fst\u00E1v\u00E1 standardem l\u00E9\u010Dby 6 cykl\u016F ABVD. Po chemoterapii je mo\u017En\u00E9 vynechat radioterapii u pacient\u016F s negativn\u00EDm n\u00E1lezem podle pozitronov\u00E9 emisn\u00ED tomografie (PET). \u010Cek\u00E1 se na dlouhodob\u00E9 v\u00FDsledky studi\u00ED se stratifikac\u00ED l\u00E9\u010Dby podle interim PET a studi\u00ED s brentuximab vedotinem v kombinaci s chemoterapi\u00ED v prvn\u00ED linii."@cs . .